Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ardelyx Inc (ARDX)
:ARDX
Holding ARDX?
Track your performance easily
ARDX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.32 - $10.13
Previous CloseN/A
Volume1.36M
Average Volume (3M)4.75M
Market Cap
$1.22B
Enterprise Value$1.54B
Total Cash (Recent Filing)$200.82M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.46
Next Earnings
Mar 05, 2025EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding236,854,260
10 Day Avg. Volume5,495,242
30 Day Avg. Volume4,747,796
Standard Deviation0.22
R-Squared0.04
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.85
Price to Cash Flow (P/CF)609.90
P/FCF Ratio839.40
Enterprise Value/Market Cap1.26
Enterprise Value/Revenue6.11
Enterprise Value/Gross Profit14.43
Enterprise Value/Ebitda-28.07
Forecast
1Y Price Target
$9.57Price Target Upside85.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Ardelyx News
PremiumCompany Announcements
Ardelyx Appoints Joseph Reilly as Principal Accounting Officer
Bulls Say, Bears Say
Bulls Say
Financial PerformanceArdelyx reported a 3Q24 total revenues top line beat of approximately $98 million, showing a 34% increase quarter-over-quarter and exceeding FactSet consensus estimates by 13%, reflecting strong growth for both Ibsrela and Xphozah.
Market PotentialIbsrela is on track to reach a $1 billion revenue target, supported by strong momentum in sales and an expanded salesforce, which could serve as a fundamental support for the stock.
Strategic InitiativesArdelyx's strategic update for 2025 and beyond highlights a clear path for long-term growth and increased market penetration for their commercial assets, Ibsrela and Xphozah, reinforcing investor confidence in the company's future prospects.
Bears Say
Investor Sentiment And Stock VolatilityA significant overhang on investor sentiment and the stock is expected until there is a resolution to the uncertainty around Medicare patient access for XPHOZAH.
Legal And Regulatory ChallengesThe District Court's dismissal of Ardelyx's lawsuit allows the CMS to include XPHOZAH in the ESRD PPS bundle, which negatively impacts the company's stock.
Sales And Market PerformanceAnalysts anticipate a substantial drop in XPHOZAH sales due to its inclusion in the Medicare bundle, leading to a downgrade of the stock rating.
---
Ownership Overview
2.57% Insiders
19.26% Mutual Funds
0.35% Other Institutional Investors
64.39% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ARDX FAQ
What was Ardelyx Inc’s price range in the past 12 months?
Ardelyx Inc lowest stock price was $4.32 and its highest was $10.13 in the past 12 months.
What is Ardelyx Inc’s market cap?
Ardelyx Inc’s market cap is $1.22B.
When is Ardelyx Inc’s upcoming earnings report date?
Ardelyx Inc’s upcoming earnings report date is Mar 05, 2025 which is in 46 days.
How were Ardelyx Inc’s earnings last quarter?
Ardelyx Inc released its earnings results on Oct 31, 2024. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.049 by $0.049.
Is Ardelyx Inc overvalued?
According to Wall Street analysts Ardelyx Inc’s price is currently Undervalued.
Does Ardelyx Inc pay dividends?
Ardelyx Inc does not currently pay dividends.
What is Ardelyx Inc’s EPS estimate?
Ardelyx Inc’s EPS estimate is <0.01.
How many shares outstanding does Ardelyx Inc have?
Ardelyx Inc has 236,854,260 shares outstanding.
What happened to Ardelyx Inc’s price movement after its last earnings report?
Ardelyx Inc reported an EPS of $0 in its last earnings report, beating expectations of -$0.049. Following the earnings report the stock price went up 3.748%.
Which hedge fund is a major shareholder of Ardelyx Inc?
Among the largest hedge funds holding Ardelyx Inc’s share is Oracle Investment Management Inc. It holds Ardelyx Inc’s shares valued at 9M.
---
Ardelyx Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.57 (85.47% Upside)
$9.57 (85.47% Upside)
Blogger Sentiment
Bullish
ARDX Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 86.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.4%
Last 30 Days ▲ 0.5%
Last 30 Days ▲ 0.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.19%
12-Months-Change
Fundamentals
Return on Equity
-41.54%
Trailing 12-Months
Asset Growth
27.12%
Trailing 12-Months
Company Description
Ardelyx Inc
Ardelyx, Inc. is a biopharmaceutical company, which engages in the research, development and commercialization of medicine for the treatment of renal diseases. It focuses on the formulation of programs directed toward treating gastrointestinal and irritable bowel syndrome with constipations. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Fremont, CA.
---
ARDX Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant revenue growth and strong market reception for Ardelyx's products, IBSRELA and XPHOZAH. However, challenges remain with CMS coverage uncertainties and increased operating expenses. Legal and legislative efforts to address policy changes are ongoing.Read More>---
ARDX Stock 12 Month Forecast
Average Price Target
$9.57
▲(85.47% Upside)
Technical Analysis
Karyopharm Therapeutics
―
Aurinia Pharmaceuticals
―
Fate Therapeutics
―
Kura Oncology
―
Seres Therapeutics
―
Eloxx Pharmaceuticals
―
Best Analysts Covering ARDX
1 Year
1 Year Success Rate
8/16 ratings generated profit
1 Year Average Return
+62.31%
reiterated a buy rating 3 months ago
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +62.31% per trade.
---